Baker McKenzie advised CureVac, a global biopharmaceutical company developing transformative medicines based on messenger ribonucleic acid (mRNA), on restructuring its existing collaboration with GSK into a new licensing agreement, allowing each company to prioritize investment
Tags :Julia Schieber
Seamless Therapeutics, a German biotechnology firm, has successfully concluded a USD12.5 million Seed Financing, a university carve-out including equity financing, in-licensing of an innovative patent portfolio from Technische Universität Dresden and hiring of key
Baker McKenzie has advised CTS Corporation, a renowned designer and manufacturer of sensors, actuators and electronic components, on the acquisition of Swiss-based maglab, a company with expertise in magnetic system design, primarily focused on custom
Baker McKenzie has advised Tandem Diabetes Care, a global insulin delivery and diabetes technology company, on its purchase of AMF Medical, a privately held Swiss insulin patch pump developer. AMF Medical’s technology aligns well
Baker McKenzie has advised the founders and owners of Digital Republic on selling the company to mobilezone Group. Digital Republic is a leading online provider of mobile internet (Mobile Virtual Network Operator, MVNO) in Switzerland.
Baker McKenzie has advised Mövenpick Group in selling the multi-brand international catering company Marché International to Lagardère Travel Retail, the travel retail division of the French Lagardère Group. The sale completes the
Baker McKenzie Switzerland has advised publicly listed Datwyler, a specialist for system-critical elastomer components, on its acquisition of Swiss startup company CTsystems. With this acquisition, Datwyler is able to strengthen its position for the future
Baker McKenzie expands its membership with the incorporation of three new partners in Switzerland and 116 new partners worldwide. In this sense, Baker McKenzie has elected 75 new partners, an increase of 22% from 2021, demonstrating clear and growing
Baker McKenzie advised Chord Therapeutics (Chord) and its shareholders on the sale of all the shares in Chord to Merck KGaA (Merck). The acquisition is subject to regulatory clearances. This strategic acquisition will enable Merck
Mérieux Equity Partners, France (MxEP) has agreed to invest EUR 40 million into Swixx Biopharma, Switzerland (Swixx), taking a minority position. SIX listed HBM Healthcare Investments who had invested in Swixx in 2017, will co-invest alongside
